How do you decide on the duration of endocrine therapy for premenopausal women who receive chemotherapy and AI/ovarian suppression according to TEXT/SOFT?  

Women who have a higher than average risk of recurrence (those who receive chemotherapy, younger than 35 Years, stages II or III ....) derive the most benefit from  endocrine therapy +ovarian suppression (using monthly GNRH agonists) for 5 years based on TEXT and SOFT  in DFS. The joint an...

The SOFT and TEXT trials have provided clear evidence on managing endocrine therapy in the first 5 years; based on these findings, we can consider 5 years as the optimal duration of ovarian function suppression when this treatment is needed. Considering the lack of efficacy and particularly of safet...

This is a good question. The duration of anti estrogen therapy was not addressed by SOFT/TEXT trials. The recent data presented at SABCS showed the benefit of ovarian suppression in premenopausal women with high risk disease. The ABCsG-16 data presented at SABCS was in postmenopausal women and this ...